PROCEPT BioRobotics Corporation (PRCT)
NASDAQ: PRCT · Real-Time Price · USD
27.00
+0.54 (2.04%)
May 28, 2026, 12:33 PM EDT - Market open
PROCEPT BioRobotics Revenue
PROCEPT BioRobotics had revenue of $83.13M in the quarter ending March 31, 2026, with 20.20% growth. This brings the company's revenue in the last twelve months to $322.02M, up 29.26% year-over-year. In the year 2025, PROCEPT BioRobotics had annual revenue of $308.05M with 37.22% growth.
Revenue (ttm)
$322.02M
Revenue Growth
+29.26%
P/S Ratio
4.60
Revenue / Employee
$362,640
Employees
888
Market Cap
1.54B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 308.05M | 83.56M | 37.22% |
| Dec 31, 2024 | 224.50M | 88.31M | 64.84% |
| Dec 31, 2023 | 136.19M | 61.18M | 81.55% |
| Dec 31, 2022 | 75.01M | 40.54M | 117.60% |
| Dec 31, 2021 | 34.47M | 26.76M | 346.72% |
| Dec 31, 2020 | 7.72M | 1.55M | 25.09% |
| Dec 31, 2019 | 6.17M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AdaptHealth | 3.29B |
| Enovis | 2.28B |
| Integra LifeSciences Holdings | 1.64B |
| Inspire Medical Systems | 915.25M |
| Neogen | 870.56M |
| Alphatec Holdings | 787.08M |
| Avanos Medical | 715.90M |
| NovoCure | 674.41M |
PRCT News
- 4 hours ago - PROCEPT BioRobotics® Advances Prostate Cancer Program with WATER IV Study Enrollment Completion and Expanded IDE Approval - GlobeNewsWire
- 14 days ago - AUA Guidelines Strengthen Recommendation for Aquablation® Therapy - GlobeNewsWire
- 15 days ago - PROCEPT BioRobotics Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 27 days ago - PROCEPT BioRobotics® to Attend Three Upcoming Investor Conferences in May & June - GlobeNewsWire
- 4 weeks ago - Procept BioRobotics price target raised to $35 from $28 at Piper Sandler - TheFly
- 4 weeks ago - Procept BioRobotics price target raised to $28 from $27 at Baird - TheFly
- 4 weeks ago - Procept BioRobotics affirms FY26 revenue $390M-$410M, consensus $395.9M - TheFly
- 4 weeks ago - Procept BioRobotics reports Q1 EPS (56c), consensus (55c) - TheFly